## Drug Status Report

**Drug:** 5-(1,1-Dimethyloctyl)-2-(3-hydroxycyclohexyl)phenol

**Drug Name Status**: 5-(1,1-Dimethyloctyl)-2-(3-hydroxycyclohexyl)phenol is the chemical name.

Chemical Name: 5-(1,1-Dimethyloctyl)-2-(3-hydroxycyclohexyl)phenol

## **Chemical structure:**

**Molecular Formula:** C<sub>22</sub>H<sub>36</sub>O<sub>2</sub>

Pharmacological class / Application: cannabinoid

## **International status:**

US: The substance is not currently listed on the schedules to the US Controlled Substances Act and is not mentioned on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control nor the Green List - List of Psychotropic Substances under International Control.

Canadian Status: 5-(1,1-Dimethyloctyl)-2-(3-hydroxycyclohexyl)phenol is a synthetic substance that has been assessed¹ in four cannabinoid behavioural evaluations and found to be almost two times as active as delta9-tetrahydrocannabinol (THC). Status decisions have been made on several other synthetic cannabinoid receptor agonists and antagonists. See decisions for anandamide; methanandamide; WIN 555212; JWH 015; O-2050, CP55940, AM630, AM251 and SR 141716A. Cannabinoid receptor agonists have been declared to be included within item 1 of Schedule II to the CDSA by virtue of being "similar synthetic preparations." Cannabinoid receptor antagonists have been declared to fall outside item 1 of Schedule II to the CDSA. 5-(1,1-Dimethyloctyl)-2-(3-hydroxycyclohexyl)phenol is a synthetic preparation similar to the

<sup>&</sup>lt;sup>1</sup> Compton DR, Johnson MR, Melvin LS, Martin BR., Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther. 1992 Jan;260(1):201-9.

cannabinoids and therefore included in item 1 of Schedule II.

Recommendation: 5-(1,1-Dimethyloctyl)-2-(3-hydroxycyclohexyl)phenol is included in item 1 of Schedule II to the CDSA and is a controlled substance.

August 13, 2008